2025-09-09 - Analysis Report
Okay, here's a report summarizing the provided data for Recursion Pharmaceuticals Inc. (RXRX), formatted as requested:

**Report: Recursion Pharmaceuticals Inc. (RXRX) Analysis**

Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (RXRX):** -47.08%
*   **Cumulative Return (VOO):** 38.92%
*   **Performance Differential:** -86.01%

    *   **Range:** (Max: 35.8, Min: -89.0)
    *   **Current Difference:** -87.5
    *   **Relative Difference:** 1.2

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period. The relative difference indicates RXRX is near the lower end of its historical performance range compared to the index.

| Year       | CAGR   | MDD     | Alpha   | Beta  | Cap(B) |
|------------|--------|---------|---------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%   | 0.0%    | -0.0  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%   | -24.0%  | 0.0   | 3.0    |
| 2023-2025  | 4.0%   | 73.6%   | -47.0%  | 0.0   | 2.0    |

**Analysis:**

*   **CAGR:** Compound Annual Growth Rate is unstable
*   **MDD:** Maximum Drawdown is very high and remain the same over the periods, indicating significant risk.
*   **Alpha:** Alpha is negative, indicating underperformance relative to the benchmark (S&P 500).
*   **Beta:** Beta is close to zero, suggesting that the stock's price is not correlated with the overall market movements.
*   **Cap(B):** Market capitalization has decreased over time, indicating that the company's value has decreased.

**2. Recent Price Action**

*   **Current Price:** 4.61
*   **Last Market Data:** Price: 4.62, Previous Close: 4.61, Change: 0.22
*   **5-Day Moving Average:** 4.614
*   **20-Day Moving Average:** 5.0377
*   **60-Day Moving Average:** 5.345

**Analysis:** The stock price shows a very slight increase in the most recent trading session. The price is below all moving averages, indicating a downtrend, with the 5-day MA closing in on the current price, signalling potential short-term stabilisation.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 18.48 (Oversold)
*   **PPO:** -0.9388
*   **Hybrid Signal:** Cash_70%_Sell (Caution - MRI: 0.34)
*   **Recent (20-Day) Relative Difference Change:** 1.2 (+) - Short-term increase
*   **Expected Return:** -2215.7% (Long-term, vs. S&P 500)

**Analysis:**

*   The stock is currently in oversold territory based on the RSI.
*   The PPO is negative, confirming the downtrend.
*   Despite the low MRI, the Hybrid Signal recommends a high cash position and suggests selling, indicating caution.
*   The extremely negative expected return signals a significant projected underperformance compared to the S&P 500 over a long-term investment horizon.
*   The recent slight increase in price (change 0.22 from previous close) suggests a potential bounce, although caution is warranted.

**4. Recent News & Significant Events**

*   **[2025-09-03]** Rallybio Receives $12.5 Million Equity Milestone From Recursion.
*   **[2025-08-29]** Motley Fool: "If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago..." (Implies poor historical returns).
*   **[2025-08-28]** Recursion Expands Rare Disease Pipeline with REV102 Acquisition.
*   **[2025-08-28]** Motley Fool: Mentions Recursion as an Nvidia-backed AI stock.
*   **[2025-08-27]** Recursion to Participate in Upcoming Investor Conferences.
*   **[2025-08-25]** Motley Fool: "1 Reason to Buy This Beaten-Down AI Stock, and 2 Reasons to Sell."

**Analysis:** Recent news is mixed.  The Rallybio milestone suggests positive developments. The Motley Fool articles offer conflicting views (buy/sell) and highlight past underperformance. The rare disease pipeline expansion and AI connection are potential positives.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.62)
*   **Opinions:** 6 analysts
*   **Target Price:** Avg: 6.47 / High: 10.00 / Low: 3.00
*   **Recent Rating Changes:** (No specific changes provided)

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price implies potential upside, but the wide range (3.00 - 10.00) indicates uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.50 | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.40 | 0.01 B$   |
| 2025-08-05 | -0.40 | 0.01 B$   |

**Analysis:** The company consistently reports negative EPS (losses). Revenue is relatively low and fluctuates.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.02B   | -5.54%        |
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-06-30   | $0.92B   | -18.70%  |
| 2025-03-31   | $0.93B   | -21.68%  |
| 2024-12-31   | $1.03B   | -17.29%  |
| 2024-09-30   | $0.52B   | -18.27%  |
| 2024-06-30   | $0.58B   | -16.69%  |

**Analysis:**

*   **Revenue:** Volatile and generally low.
*   **Profit Margin:** Mostly negative, indicating struggles with profitability.  There were two positive margins in 2024, but more recent margins are negative.
*   **Equity:** Equity has decreased in the most recent quarters.
*   **ROE:** Consistently negative, reflecting poor returns on equity.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) is a company with significant challenges. It has severely underperformed the S&P 500. Financials show low and inconsistent revenue, negative profit margins, and negative ROE. The stock is currently oversold, but technical indicators and news suggest caution. Analyst consensus is "Hold," but the wide target price range reflects uncertainty. Despite potential positives from AI and pipeline expansion, the overall picture suggests high risk and potential for continued underperformance, with a strong recommendation from one signal to hold a very high cash position. Long term prospects are looking very dim.
